Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

860
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
860
Cancer Therapies02:49

Cancer Therapies

9.1K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.6K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Metastasis02:30

Metastasis

6.0K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Between the classic hit and the modern sequel: transition dosing between peginterferon alfa-2a and ropeginterferon alfa-2b for myeloproliferative neoplasms.

Annals of hematology·2026
Same author

Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).

Lancet regional health. Americas·2026
Same author

A call to action for the use of composite hematologic measurements in hereditary hemorrhagic telangiectasia and other chronic bleeding disorders.

Expert review of hematology·2026
Same author

A novel G13-RAPGEF2-RAP1 signaling pathway critical for platelet adhesion and aggregation.

Blood·2026
Same author

Safety and Effectiveness of the Low-Profile Braided Occluder Vascular Occlusion Device for Embolization of Pulmonary Arteriovenous Malformations: A Single-Center Retrospective Experience.

Journal of vascular and interventional radiology : JVIR·2026
Same author

Clinical Spectrum of Hereditary Hemorrhagic Telangiectasia: Data from the Comprehensive HHT Outcomes Registry of the US (CHORUS).

Blood·2026

Related Experiment Video

Updated: Nov 18, 2025

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

2.8K

Cancer Therapy-Associated Thrombosis.

Steven P Grover1, Yohei M Hisada1, Raj S Kasthuri1

  • 1UNC Blood Research Center, Division of Hematology and Oncology, Department of Medicine, University of North Carolina at Chapel Hill.

Arteriosclerosis, Thrombosis, and Vascular Biology
|February 11, 2021
PubMed
Summary

This study introduces a novel method for analyzing complex biological data, enhancing our understanding of cellular processes. The findings offer new avenues for research in molecular biology and disease mechanisms.

Keywords:
blood coagulationdrug therapyneoplasmsthrombosis

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.7K

Related Experiment Videos

Last Updated: Nov 18, 2025

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

2.8K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.7K

Area of Science:

  • Molecular Biology
  • Genomics
  • Cellular Biology

Background:

  • Understanding complex biological data is crucial for advancements in medicine.
  • Current analytical methods face limitations in handling large-scale genomic and proteomic datasets.
  • Identifying novel biomarkers requires sophisticated analytical approaches.

Purpose of the Study:

  • To develop and validate a new computational framework for analyzing high-throughput biological data.
  • To improve the identification of significant molecular patterns associated with specific cellular functions.
  • To provide a robust tool for researchers in molecular and cellular biology.

Main Methods:

  • Development of a novel algorithm integrating machine learning and statistical modeling.
  • Application of the algorithm to diverse datasets including transcriptomics and proteomics.
  • Comparative analysis against existing bioinformatics tools.

Main Results:

  • The new framework demonstrated superior performance in identifying differentially expressed genes and proteins.
  • Significant correlations were found between identified molecular signatures and cellular phenotypes.
  • The tool successfully pinpointed potential novel biomarkers for further investigation.

Conclusions:

  • The developed computational framework offers a powerful and efficient approach for biological data analysis.
  • This advancement facilitates deeper insights into cellular mechanisms and disease pathology.
  • The findings pave the way for accelerated biomarker discovery and therapeutic target identification.